What Is Wegovy and Its Main Purpose?
Wegovy (semaglutide) is an FDA-approved injectable prescription medication for chronic weight management in adults with obesity or overweight with weight-related conditions like hypertension or type 2 diabetes. It activates GLP-1 receptors in the brain to reduce appetite and food intake, leading to sustained weight loss of 15-20% on average in clinical trials.[1]
How Do You Use Wegovy?
Administered as a once-weekly subcutaneous injection via a pre-filled, single-dose pen. Start at 0.25 mg, titrating up to a 2.4 mg maintenance dose over 16 weeks to minimize side effects. Pens are disposable and stored in the fridge; they last up to 5 weeks at room temperature after first use.[1]
What Weight Loss Results Can Users Expect?
In the STEP trials, participants on 2.4 mg lost 15-17% body weight over 68 weeks versus 2-3% on placebo. About 83% achieved at least 5% loss, and 50% lost 15% or more. Results vary by adherence, diet, and exercise; weight regain occurs if discontinued.[1][2]
Common Side Effects and Risks
Most frequent: nausea (44%), diarrhea (30%), vomiting (24%), constipation (24%), and abdominal pain. Serious risks include thyroid tumors (boxed warning), pancreatitis, gallbladder issues, low blood sugar (with insulin), and kidney problems. Not for type 1 diabetes or history of medullary thyroid carcinoma.[1]
How Does Wegovy Differ from Ozempic or Saxenda?
Wegovy has the highest approved semaglutide dose (2.4 mg) for weight loss, while Ozempic (up to 2 mg) focuses on diabetes with off-label weight use. Saxenda (liraglutide) requires daily injections and yields less weight loss (5-10%). All are GLP-1 agonists, but Wegovy's weekly dosing and potency drive superior obesity results.[1][2]
Cost and Insurance Coverage
List price is about $1,350 per month (four pens). Savings cards from Novo Nordisk reduce it to $0-$500 for eligible insured patients. Medicare Part D covers it for obesity in some cases post-2024 changes; commercial insurance varies widely.[3]
Who Makes Wegovy and When Do Patents Expire?
Novo Nordisk manufactures Wegovy. Key U.S. patents on semaglutide formulation expire in 2030-2032, with pediatric exclusivity potentially extending to 2033. Challenges from competitors like Teva could shorten this; check DrugPatentWatch.com for litigation updates.[4]
[1]: FDA Label - https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/215256s007lbl.pdf
[2]: NEJM STEP Trials - https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
[3]: Novo Nordisk Pricing - https://www.wegovy.com/coverage-and-savings/check-your-cost-and-coverage.html
[4]: DrugPatentWatch - https://www.drugpatentwatch.com/p/tradename/WEGOVY